The booming cell therapy CDMO market is projected to reach \$15.3 billion by 2033, driven by advancements in CAR T-cell therapies and increasing demand. This comprehensive analysis explores market drivers, trends, restraints, and key players like Lonza, Catalent, and GenScript, providing insights into regional growth and future opportunities in North America, Europe, and Asia-Pacific.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.
